Many commentaries and papers have appeared on this theme but most take a predominantly US perspective. There is a useful summary in a Dereck Lowe 2016 blogpost 'Drugs Purely From Academia'. This includes a list of compounds distilled from 'The importance of new companies for drug discovery: origins of a decade of new drugs where the focus was on the contribution of smaller companies as newer discovering organisations. Another publication covering some of the same ground but more specifically looking at the academic contribution was a 2011 paper 'The Role of Public-Sector Research in the Discovery of Drugs and Vaccines' ( PMID 21306239), This found that over 40 years, 93 small-molecule drugs were discovered through research carried out in the academic sector. They also state this sector has contributed to the discovery of ~10% -20% of all NDAs from 1990 to 2007. However, these papers have not reported statistics for the direct involvement of ADEV teams.